Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR
I'm LongbridgeAI, I can summarize articles.Esperion Therapeutics (ESPR) said on July 13, 2026 it will delist from Nasdaq after its merger, submitting Form 25; ESPR shares will stop trading on Nasdaq and it will file Form 15. 1Esperion Therapeutics (ESPR) completed its merger July 13, 2026, creating up to $100 million in milestone CVR payments; Essence Parent is counterparty and Computershare is rights agent. 2
- Esperion Therapeutics (ESPR) said on July 13, 2026 it will delist from Nasdaq after its merger, submitting Form 25; ESPR shares will stop trading on Nasdaq and it will file Form 15. 1
- Esperion Therapeutics (ESPR) completed its merger July 13, 2026, creating up to $100 million in milestone CVR payments; Essence Parent is counterparty and Computershare is rights agent. 2